Rare Pediatric Non-Hodgkin Lymphomas: A Report From Children's Oncology Group Study ANHL 04B1
Background Non‐Hodgkin lymphoma (NHL) is a relatively common malignancy in pediatric patients; however, a small subgroup have unusual lymphoma subtypes for the pediatric population. Procedure The Children's Oncology Group Rare and Cutaneous NHL registry's (protocol ANHL 04B1) main objectiv...
Saved in:
Published in | Pediatric blood & cancer Vol. 63; no. 5; pp. 794 - 800 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.05.2016
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
ISSN | 1545-5009 1545-5017 |
DOI | 10.1002/pbc.25881 |
Cover
Summary: | Background
Non‐Hodgkin lymphoma (NHL) is a relatively common malignancy in pediatric patients; however, a small subgroup have unusual lymphoma subtypes for the pediatric population.
Procedure
The Children's Oncology Group Rare and Cutaneous NHL registry's (protocol ANHL 04B1) main objectives were to determine the pathologic, biologic, and clinical features of rare and cutaneous pediatric NHL and establish a bank of centrally reviewed tissue specimens. We report the clinical data, treatment data, and outcome for rare pediatric NHL.
Results
In 101 lymphomas, there is a 97.8% concordance between the reviewing study pathologists and an 87.6% concordance between the central and institutional pathology review. Samples in the specimen bank include primary tumor tissue that is snap frozen, in paraffin blocks, or H&E‐stained and unstained paraffin slides as well as blood, serum, and bone marrow. This descriptive analysis shows that children with pediatric follicular lymphoma, mucosa‐associated lymphoid tissue, nodal marginal zone lymphoma, primary cutaneous, primary central nervous system lymphoma, and subcutaneous panniculitis‐like T‐cell lymphomas have 100% survival at a median of 2 years from enrollment. There are early deaths, mostly from progressive disease, in subjects with peripheral T‐cell (not otherwise specified), NKT, and hepatosplenic T‐cell lymphomas.
Conclusions
This registry provides high‐quality biologic specimens with clinical data to investigators working on the biology of these unusual pediatric diseases. |
---|---|
Bibliography: | COG Chair's - No. U10CA098543 Human Specimen Banking in NCI-Sponsored Clinical Trials; Grant number: - No. U24CA114766; Grant sponsor Statistics & Data Center - No. U10CA098413 ark:/67375/WNG-R34ZC4N1-N Statistics & Data Center; Grant number: - No. U10CA098413. istex:F8E60FDC11D1B0000005191345C348E33D0E13B9 COG Chair's; Grant number: - No. U10CA098543; Grant sponsor ArticleID:PBC25881 Human Specimen Banking in NCI-Sponsored Clinical Trials - No. U24CA114766 Grant sponsor: COG Chair's; Grant number: U10CA098543; Grant sponsor: Human Specimen Banking in NCI‐Sponsored Clinical Trials; Grant number: U24CA114766; Grant sponsor: Statistics & Data Center; Grant number: U10CA098413. Chibuzo O'Suoji and Jennifer Welch are co‐first authors. Conflict of interest: S.J.S. is currently employed by Genentech/Roche. The authors report no relevant conflicts of interest related to the work presented here. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
ISSN: | 1545-5009 1545-5017 |
DOI: | 10.1002/pbc.25881 |